TY  - CONF
AU  - Stanković, Tamara
AU  - Batinić, Bojan
AU  - Savić, Miroslav
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3300
PB  - Elsevier Science BV, Amsterdam
C3  - European Neuropsychopharmacology
T1  - A novel positive modulator of alpha 4-GABAA receptors, XHe-III-74, reduces ethanol intake in mouse "drinking in the dark" model
VL  - 29
IS  - Supplement 1
SP  - S576
EP  - S577
DO  - 10.1016/j.euroneuro.2018.11.855
ER  - 

@conference{
author = "Stanković, Tamara and Batinić, Bojan and Savić, Miroslav",
year = "2019",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Neuropsychopharmacology",
title = "A novel positive modulator of alpha 4-GABAA receptors, XHe-III-74, reduces ethanol intake in mouse "drinking in the dark" model",
volume = "29",
number = "Supplement 1",
pages = "S576-S577",
doi = "10.1016/j.euroneuro.2018.11.855"
}

Stanković, T., Batinić, B.,& Savić, M.. (2019). A novel positive modulator of alpha 4-GABAA receptors, XHe-III-74, reduces ethanol intake in mouse "drinking in the dark" model. in European Neuropsychopharmacology
Elsevier Science BV, Amsterdam., 29(Supplement 1), S576-S577.
https://doi.org/10.1016/j.euroneuro.2018.11.855

Stanković T, Batinić B, Savić M. A novel positive modulator of alpha 4-GABAA receptors, XHe-III-74, reduces ethanol intake in mouse "drinking in the dark" model. in European Neuropsychopharmacology. 2019;29(Supplement 1):S576-S577.
doi:10.1016/j.euroneuro.2018.11.855 .

Stanković, Tamara, Batinić, Bojan, Savić, Miroslav, "A novel positive modulator of alpha 4-GABAA receptors, XHe-III-74, reduces ethanol intake in mouse "drinking in the dark" model" in European Neuropsychopharmacology, 29, no. Supplement 1 (2019):S576-S577,
https://doi.org/10.1016/j.euroneuro.2018.11.855 . .

TY  - JOUR
AU  - Batinić, Bojan
AU  - Stanković, Tamara
AU  - Stephen, Michael
AU  - Kodali, Revathi
AU  - Tiruveedhula, Veera V.
AU  - Li, Guanguan
AU  - Scholze, Petra
AU  - Marković, Bojan
AU  - Obradović, Aleksandar
AU  - Ernst, Margot
AU  - Cook, James M.
AU  - Savić, Miroslav
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3070
AB  - It is unclear whether GABA(A) receptors (GABA(A)Rs) that contain the alpha 3-subunit are substantially involved in the anxiolytic effects of benzodiazepines (BDZs). In the present study, we tested YT-III-31, a newer BDZ ligand with functional preference for alpha 3 ss gamma 2 GABA(A) Rs, in two paradigms of unconditioned anxiety, the open field and elevated plus maze in rats. The effective dose of YT-III-31 (2 mg/kg) displayed a clear anxiolytic-like profile, unhampered by sedative action, in both tests. At a higher dose (10 mg/kg), YT-III-31 induced ataxia in the rotarod and sedation in spontaneous locomotor activity test. The latter effect was preventable by flumazenil and ss CCt, the non-selective and alpha 1 ss gamma 2 GABA(A)R affinity-selective antagonist, respectively, demonstrating that sedative properties of YT-III-31, when attained, are mediated by the alpha 1 gamma 2 site. To elucidate the receptor substrate of subtle behavioral differences between YT-III-31 and diazepam, we approximated in vivo receptor potentiation for both ligands, based on estimated unbound concentrations in rat brains. Far different from diazepam, YT-III-31 has significantly lower affinity for the alpha 1 gamma 2 over other BDZ-sensitive sites, and at lower doses (1-2 mg/kg) was devoid of potentiation at alpha 1 ss gamma 2 GABA(A)Rs. The approximation approach revealed a modest selectivity of YT-III-31 for alpha 3 gamma 2- in comparison to alpha 2 gamma 2 and alpha 5 gamma 2 binding sites, suggesting that its anxiolytic-like activity may not necessarily or predominantly reflect potentiation at alpha 3 ss gamma 2 GABA(A)Rs. Nonetheless, as the anxiolytic effects are achievable at a dose devoid of any sedative potential, and having favorable safety (cytotoxicity) and metabolic stability profile, YT-III-31 represents a valuable candidate for further translational research.
PB  - Elsevier Science BV, Amsterdam
T2  - European Neuropsychopharmacology
T1  - Attaining in vivo selectivity of positive modulation of alpha 3 ss gamma 2 GABA(A) receptors in rats: A hard task!
VL  - 28
IS  - 8
SP  - 903
EP  - 914
DO  - 10.1016/j.euroneuro.2018.05.014
ER  - 

@article{
author = "Batinić, Bojan and Stanković, Tamara and Stephen, Michael and Kodali, Revathi and Tiruveedhula, Veera V. and Li, Guanguan and Scholze, Petra and Marković, Bojan and Obradović, Aleksandar and Ernst, Margot and Cook, James M. and Savić, Miroslav",
year = "2018",
abstract = "It is unclear whether GABA(A) receptors (GABA(A)Rs) that contain the alpha 3-subunit are substantially involved in the anxiolytic effects of benzodiazepines (BDZs). In the present study, we tested YT-III-31, a newer BDZ ligand with functional preference for alpha 3 ss gamma 2 GABA(A) Rs, in two paradigms of unconditioned anxiety, the open field and elevated plus maze in rats. The effective dose of YT-III-31 (2 mg/kg) displayed a clear anxiolytic-like profile, unhampered by sedative action, in both tests. At a higher dose (10 mg/kg), YT-III-31 induced ataxia in the rotarod and sedation in spontaneous locomotor activity test. The latter effect was preventable by flumazenil and ss CCt, the non-selective and alpha 1 ss gamma 2 GABA(A)R affinity-selective antagonist, respectively, demonstrating that sedative properties of YT-III-31, when attained, are mediated by the alpha 1 gamma 2 site. To elucidate the receptor substrate of subtle behavioral differences between YT-III-31 and diazepam, we approximated in vivo receptor potentiation for both ligands, based on estimated unbound concentrations in rat brains. Far different from diazepam, YT-III-31 has significantly lower affinity for the alpha 1 gamma 2 over other BDZ-sensitive sites, and at lower doses (1-2 mg/kg) was devoid of potentiation at alpha 1 ss gamma 2 GABA(A)Rs. The approximation approach revealed a modest selectivity of YT-III-31 for alpha 3 gamma 2- in comparison to alpha 2 gamma 2 and alpha 5 gamma 2 binding sites, suggesting that its anxiolytic-like activity may not necessarily or predominantly reflect potentiation at alpha 3 ss gamma 2 GABA(A)Rs. Nonetheless, as the anxiolytic effects are achievable at a dose devoid of any sedative potential, and having favorable safety (cytotoxicity) and metabolic stability profile, YT-III-31 represents a valuable candidate for further translational research.",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Neuropsychopharmacology",
title = "Attaining in vivo selectivity of positive modulation of alpha 3 ss gamma 2 GABA(A) receptors in rats: A hard task!",
volume = "28",
number = "8",
pages = "903-914",
doi = "10.1016/j.euroneuro.2018.05.014"
}

Batinić, B., Stanković, T., Stephen, M., Kodali, R., Tiruveedhula, V. V., Li, G., Scholze, P., Marković, B., Obradović, A., Ernst, M., Cook, J. M.,& Savić, M.. (2018). Attaining in vivo selectivity of positive modulation of alpha 3 ss gamma 2 GABA(A) receptors in rats: A hard task!. in European Neuropsychopharmacology
Elsevier Science BV, Amsterdam., 28(8), 903-914.
https://doi.org/10.1016/j.euroneuro.2018.05.014

Batinić B, Stanković T, Stephen M, Kodali R, Tiruveedhula VV, Li G, Scholze P, Marković B, Obradović A, Ernst M, Cook JM, Savić M. Attaining in vivo selectivity of positive modulation of alpha 3 ss gamma 2 GABA(A) receptors in rats: A hard task!. in European Neuropsychopharmacology. 2018;28(8):903-914.
doi:10.1016/j.euroneuro.2018.05.014 .

Batinić, Bojan, Stanković, Tamara, Stephen, Michael, Kodali, Revathi, Tiruveedhula, Veera V., Li, Guanguan, Scholze, Petra, Marković, Bojan, Obradović, Aleksandar, Ernst, Margot, Cook, James M., Savić, Miroslav, "Attaining in vivo selectivity of positive modulation of alpha 3 ss gamma 2 GABA(A) receptors in rats: A hard task!" in European Neuropsychopharmacology, 28, no. 8 (2018):903-914,
https://doi.org/10.1016/j.euroneuro.2018.05.014 . .

TY  - CONF
AU  - Stanković, Tamara
AU  - Batinić, Bojan
AU  - Santrač, Anja
AU  - Marković, Bojan
AU  - Drobac, Milica
AU  - Arsenijević, Jelena
AU  - Savić, Miroslav
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5284
AB  - Cilj ove studije bio je da se ispita da li akutni tretman ligandom XHe‐III‐74, novim
pozitivnim modulatorom α4‐GABAA receptora, može smanjiti unos alkohola u mišijem
modelu „pijenja u mraku” (eng. drinking in the dark – DID).
Eksperimenti su sprovedeni na odraslim miševima soja C57BL/6. Moguće
sedativno dejstvo XHe‐III‐74 (0,5; 2 ili 5 mg/kg, i.p.) ispitano je u testu spontane
lokomotorne aktivnosti (SLA). Prvog dana jednog ciklusa DID eksperimenta svaka
životinja imala je dvočasovni pristup alkoholu (etanol 20%, v/v). Drugog dana tretman
je primenjivan 20 minuta pre pristupa alkoholu, a trećeg dana pacovi nisu tretirani
ničim. U svim DID eksperimentima svaka životinja je prošla kroz četiri ciklusa tako da je
u svakom primila jednu od tri doze tretmana ili placebo. U prvom DID eksperimentu
testirali smo efekat XHe‐III‐74 (0,8; 2 ili 5 mg/kg) na unos vode (n=12, po dozi), dok
smo u drugom testirali efekat istih doza na unos alkohola (n=14). Ekekat referetnog
leka, naltreksona (1; 4 ili 16 mg/kg) testiran je u trećem eksperimentu.
U SLA testu, nijedna od odabranih doza XHe‐III‐74 nije smanjila pređeni put životinje
(F3,20=0,48; p=0,703). U prvom DID eksperiementu, tretman XHe‐III‐74 nije uticao na
unos vode (F3,33=0,39; p=0,763). Unos alkohola, meren u drugom DID eksperimentu,
izmenjen je pod dejstvom XHe‐III‐74 tretmana (F3,39=7,41; p<0,001), gde je doza XHe‐
III‐74 od 5 mg/kg značajno smanjila unos u poređenju sa kontrolom (p<0,001). U
trećem eksperimentu, naltrekson je značajno smanjio unos alkohola (F60,3=22.18;
p<0,001), i to u sve tri doze: 1 mg/kg (p<0,001); 4 mg/kg (p<0,001) i 16 mg/kg
(p<0,001).
Uz očekivani izostanak sedativnog dejstva, XHe‐III‐74, pozitivni modulator α4‐
GABAA receptora, ispoljio je evidentan potencijal za smanjenje unosa alkohola u
mišijem DID modelu, koji se može porediti sa onim postignutim primenom naltreksona,
referentnog leka u terapiji poremećaja unosa alkohola.
AB  - The present study aimed to investigate whether acute treatment with XHe‐III‐74,
a novel positive modulator of α4‐GABAA receptors, may reduce alcohol intake in mouse
model of „drinking in the dark” (DID).
All experiments were conducted on adult C57BL/6 mice. Potential sedative
properties of XHe‐III‐74, (0.5, 2 or 5 mg/kg, i.p.) were assessed using spontaneous
locomotor activity (SLA) test. On the 1st day of one DID cycle each animal had 2‐h access
to ethanol (20%, v/v), on the 2nd day treatment was given 20 min before the access to
ethanol, while on the 3rd day the animal was not treated in any way. In all DID
experiments each animal passed through four cycles and respectively receive one of
three treatment doses or solvent in each cycle. In Experiment 1 we tested whether XHe‐
III‐74 (0.8, 2 or 5 mg/kg) had any effects on water intake (n=12 per treatment dose),
while in Experiment 2, the same doses were used to test potential decrease of ethanol
intake (n=14). Effects of the reference drug, naltrexone (1; 4 and 16 mg/kg) were
tested in Experiment 3 (n=21). In the SLA test, none of the selected XHe‐III‐74 doses
decreased the distance traveled (F3,20=0.48; p=0.703). In DID Experiment 1, XHe‐III‐74
treatment didn’t affect water intake (F33,3=0.39; p=0.763). Ethanol intake, measured in
Experiment 2, was affected by XHe‐III‐74 treatment (F39,3=7.41; p<0.001), with 5 mg/kg
XHe‐III‐74 significantly reducing the intake relative to control (p<0.001). In Experiment
3, naltrexone significantly affected the intake of ethanol (F60,3=22.18; p<0.001), with all
three doses reducing the intake: 1 mg/kg (p<0.001); 4 mg/kg (p<0.001) and 16 mg/kg
(p<0.001).
With expected lack of sedative actions, XHe‐III‐74, a positive modulator of α4‐
GABAARs, exhibited a clear potential for decreasing ethanol intake in mouse DID model,
comparable to that of naltrexone, a reference drug in alcohol use disorder.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Novi pozitivni modulator α4-GABAA receptora, XHE-III-74, smanjuje unos alkohola u mišijem modelu "pijenja u mraku"
T1  - A novel positive modulator of α4‐GABAA receptors, XHE-III‐74, reduces ethanol intake in mouse „drinking in the dark” model
VL  - 68
IS  - 3
SP  - 664
EP  - 665
UR  - https://hdl.handle.net/21.15107/rcub_farfar_5284
ER  - 

@conference{
author = "Stanković, Tamara and Batinić, Bojan and Santrač, Anja and Marković, Bojan and Drobac, Milica and Arsenijević, Jelena and Savić, Miroslav",
year = "2018",
abstract = "Cilj ove studije bio je da se ispita da li akutni tretman ligandom XHe‐III‐74, novim
pozitivnim modulatorom α4‐GABAA receptora, može smanjiti unos alkohola u mišijem
modelu „pijenja u mraku” (eng. drinking in the dark – DID).
Eksperimenti su sprovedeni na odraslim miševima soja C57BL/6. Moguće
sedativno dejstvo XHe‐III‐74 (0,5; 2 ili 5 mg/kg, i.p.) ispitano je u testu spontane
lokomotorne aktivnosti (SLA). Prvog dana jednog ciklusa DID eksperimenta svaka
životinja imala je dvočasovni pristup alkoholu (etanol 20%, v/v). Drugog dana tretman
je primenjivan 20 minuta pre pristupa alkoholu, a trećeg dana pacovi nisu tretirani
ničim. U svim DID eksperimentima svaka životinja je prošla kroz četiri ciklusa tako da je
u svakom primila jednu od tri doze tretmana ili placebo. U prvom DID eksperimentu
testirali smo efekat XHe‐III‐74 (0,8; 2 ili 5 mg/kg) na unos vode (n=12, po dozi), dok
smo u drugom testirali efekat istih doza na unos alkohola (n=14). Ekekat referetnog
leka, naltreksona (1; 4 ili 16 mg/kg) testiran je u trećem eksperimentu.
U SLA testu, nijedna od odabranih doza XHe‐III‐74 nije smanjila pređeni put životinje
(F3,20=0,48; p=0,703). U prvom DID eksperiementu, tretman XHe‐III‐74 nije uticao na
unos vode (F3,33=0,39; p=0,763). Unos alkohola, meren u drugom DID eksperimentu,
izmenjen je pod dejstvom XHe‐III‐74 tretmana (F3,39=7,41; p<0,001), gde je doza XHe‐
III‐74 od 5 mg/kg značajno smanjila unos u poređenju sa kontrolom (p<0,001). U
trećem eksperimentu, naltrekson je značajno smanjio unos alkohola (F60,3=22.18;
p<0,001), i to u sve tri doze: 1 mg/kg (p<0,001); 4 mg/kg (p<0,001) i 16 mg/kg
(p<0,001).
Uz očekivani izostanak sedativnog dejstva, XHe‐III‐74, pozitivni modulator α4‐
GABAA receptora, ispoljio je evidentan potencijal za smanjenje unosa alkohola u
mišijem DID modelu, koji se može porediti sa onim postignutim primenom naltreksona,
referentnog leka u terapiji poremećaja unosa alkohola., The present study aimed to investigate whether acute treatment with XHe‐III‐74,
a novel positive modulator of α4‐GABAA receptors, may reduce alcohol intake in mouse
model of „drinking in the dark” (DID).
All experiments were conducted on adult C57BL/6 mice. Potential sedative
properties of XHe‐III‐74, (0.5, 2 or 5 mg/kg, i.p.) were assessed using spontaneous
locomotor activity (SLA) test. On the 1st day of one DID cycle each animal had 2‐h access
to ethanol (20%, v/v), on the 2nd day treatment was given 20 min before the access to
ethanol, while on the 3rd day the animal was not treated in any way. In all DID
experiments each animal passed through four cycles and respectively receive one of
three treatment doses or solvent in each cycle. In Experiment 1 we tested whether XHe‐
III‐74 (0.8, 2 or 5 mg/kg) had any effects on water intake (n=12 per treatment dose),
while in Experiment 2, the same doses were used to test potential decrease of ethanol
intake (n=14). Effects of the reference drug, naltrexone (1; 4 and 16 mg/kg) were
tested in Experiment 3 (n=21). In the SLA test, none of the selected XHe‐III‐74 doses
decreased the distance traveled (F3,20=0.48; p=0.703). In DID Experiment 1, XHe‐III‐74
treatment didn’t affect water intake (F33,3=0.39; p=0.763). Ethanol intake, measured in
Experiment 2, was affected by XHe‐III‐74 treatment (F39,3=7.41; p<0.001), with 5 mg/kg
XHe‐III‐74 significantly reducing the intake relative to control (p<0.001). In Experiment
3, naltrexone significantly affected the intake of ethanol (F60,3=22.18; p<0.001), with all
three doses reducing the intake: 1 mg/kg (p<0.001); 4 mg/kg (p<0.001) and 16 mg/kg
(p<0.001).
With expected lack of sedative actions, XHe‐III‐74, a positive modulator of α4‐
GABAARs, exhibited a clear potential for decreasing ethanol intake in mouse DID model,
comparable to that of naltrexone, a reference drug in alcohol use disorder.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Novi pozitivni modulator α4-GABAA receptora, XHE-III-74, smanjuje unos alkohola u mišijem modelu "pijenja u mraku", A novel positive modulator of α4‐GABAA receptors, XHE-III‐74, reduces ethanol intake in mouse „drinking in the dark” model",
volume = "68",
number = "3",
pages = "664-665",
url = "https://hdl.handle.net/21.15107/rcub_farfar_5284"
}

Stanković, T., Batinić, B., Santrač, A., Marković, B., Drobac, M., Arsenijević, J.,& Savić, M.. (2018). Novi pozitivni modulator α4-GABAA receptora, XHE-III-74, smanjuje unos alkohola u mišijem modelu "pijenja u mraku". in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 68(3), 664-665.
https://hdl.handle.net/21.15107/rcub_farfar_5284

Stanković T, Batinić B, Santrač A, Marković B, Drobac M, Arsenijević J, Savić M. Novi pozitivni modulator α4-GABAA receptora, XHE-III-74, smanjuje unos alkohola u mišijem modelu "pijenja u mraku". in Arhiv za farmaciju. 2018;68(3):664-665.
https://hdl.handle.net/21.15107/rcub_farfar_5284 .

Stanković, Tamara, Batinić, Bojan, Santrač, Anja, Marković, Bojan, Drobac, Milica, Arsenijević, Jelena, Savić, Miroslav, "Novi pozitivni modulator α4-GABAA receptora, XHE-III-74, smanjuje unos alkohola u mišijem modelu "pijenja u mraku"" in Arhiv za farmaciju, 68, no. 3 (2018):664-665,
https://hdl.handle.net/21.15107/rcub_farfar_5284 .

TY  - JOUR
AU  - Batinić, Bojan
AU  - Santrač, Anja
AU  - Divović, Branka
AU  - Timić, Tamara
AU  - Stanković, Tamara
AU  - Obradović, Aleksandar
AU  - Joksimović, Srđan
AU  - Savić, Miroslav
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2558
AB  - Numerous basic and epidemiological studies have connected prenatal maternal immune activation with the occurrence of schizophrenia and/or autism. Depending on subtle differences in protocols of the used animal model, a variety of behavioral abnormalities has been reported. This study investigated behavioral differences in Wistar rat offspring of both genders, exposed to the 100 mu g/kg per day dose of lipopolysaccharide (LPS) in late embryogenesis (embryonic days 15 and 16), while tested at their adolescent and young adult age (postnatal days 40 and 60, respectively). Immune activation was confirmed by detecting high levels of TNF-alpha and IL-6 in dam blood withdrawn 2 h after the first dose of LPS. The animals were assessed in three consecutive trials of locomotor activity (novelty exploration, response to i.p. saline injection and challenge with 0.5 mg/kg amphetamine), Morris water maze and social interaction tests. Overt behavioral dysfunction was perceived in adult rats only, and these changes were gender-distinctive. When compared with control rats, LPS females displayed baseline hypolocomotion and a decreased reactivity to amphetamine, while LPS males exhibited spatial learning (acquisition trials) and memory (probe trial) impairments. Prenatal treatment did not affect the time spent in social interaction. As maternal exposure to LPS in late gestation resulted in behavioral changes in offspring in early adulthood, it may model schizophrenia-like, but not autism-like endophenotypes. However, lack of a potentiated response to amphetamine testified that this model could not mimic positive symptoms, but rather certain traits of cognitive dysfunction and deficit symptoms, in males and females, respectively.
PB  - Elsevier Science BV, Amsterdam
T2  - Behavioural Brain Research
T1  - Lipopolysaccharide exposure during late embryogenesis results in diminished locomotor activity and amphetamine response in females and spatial cognition impairment in males in adult, but not adolescent rat offspring
VL  - 299
SP  - 72
EP  - 80
DO  - 10.1016/j.bbr.2015.11.025
ER  - 

@article{
author = "Batinić, Bojan and Santrač, Anja and Divović, Branka and Timić, Tamara and Stanković, Tamara and Obradović, Aleksandar and Joksimović, Srđan and Savić, Miroslav",
year = "2016",
abstract = "Numerous basic and epidemiological studies have connected prenatal maternal immune activation with the occurrence of schizophrenia and/or autism. Depending on subtle differences in protocols of the used animal model, a variety of behavioral abnormalities has been reported. This study investigated behavioral differences in Wistar rat offspring of both genders, exposed to the 100 mu g/kg per day dose of lipopolysaccharide (LPS) in late embryogenesis (embryonic days 15 and 16), while tested at their adolescent and young adult age (postnatal days 40 and 60, respectively). Immune activation was confirmed by detecting high levels of TNF-alpha and IL-6 in dam blood withdrawn 2 h after the first dose of LPS. The animals were assessed in three consecutive trials of locomotor activity (novelty exploration, response to i.p. saline injection and challenge with 0.5 mg/kg amphetamine), Morris water maze and social interaction tests. Overt behavioral dysfunction was perceived in adult rats only, and these changes were gender-distinctive. When compared with control rats, LPS females displayed baseline hypolocomotion and a decreased reactivity to amphetamine, while LPS males exhibited spatial learning (acquisition trials) and memory (probe trial) impairments. Prenatal treatment did not affect the time spent in social interaction. As maternal exposure to LPS in late gestation resulted in behavioral changes in offspring in early adulthood, it may model schizophrenia-like, but not autism-like endophenotypes. However, lack of a potentiated response to amphetamine testified that this model could not mimic positive symptoms, but rather certain traits of cognitive dysfunction and deficit symptoms, in males and females, respectively.",
publisher = "Elsevier Science BV, Amsterdam",
journal = "Behavioural Brain Research",
title = "Lipopolysaccharide exposure during late embryogenesis results in diminished locomotor activity and amphetamine response in females and spatial cognition impairment in males in adult, but not adolescent rat offspring",
volume = "299",
pages = "72-80",
doi = "10.1016/j.bbr.2015.11.025"
}

Batinić, B., Santrač, A., Divović, B., Timić, T., Stanković, T., Obradović, A., Joksimović, S.,& Savić, M.. (2016). Lipopolysaccharide exposure during late embryogenesis results in diminished locomotor activity and amphetamine response in females and spatial cognition impairment in males in adult, but not adolescent rat offspring. in Behavioural Brain Research
Elsevier Science BV, Amsterdam., 299, 72-80.
https://doi.org/10.1016/j.bbr.2015.11.025

Batinić B, Santrač A, Divović B, Timić T, Stanković T, Obradović A, Joksimović S, Savić M. Lipopolysaccharide exposure during late embryogenesis results in diminished locomotor activity and amphetamine response in females and spatial cognition impairment in males in adult, but not adolescent rat offspring. in Behavioural Brain Research. 2016;299:72-80.
doi:10.1016/j.bbr.2015.11.025 .

Batinić, Bojan, Santrač, Anja, Divović, Branka, Timić, Tamara, Stanković, Tamara, Obradović, Aleksandar, Joksimović, Srđan, Savić, Miroslav, "Lipopolysaccharide exposure during late embryogenesis results in diminished locomotor activity and amphetamine response in females and spatial cognition impairment in males in adult, but not adolescent rat offspring" in Behavioural Brain Research, 299 (2016):72-80,
https://doi.org/10.1016/j.bbr.2015.11.025 . .

TY  - CONF
AU  - Batinić, Bojan
AU  - Stanković, Tamara
AU  - Poe, Michael M.
AU  - Cook, James M.
AU  - Savić, Miroslav
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2654
PB  - Elsevier Science BV, Amsterdam
C3  - European Neuropsychopharmacology
T1  - Attaining in vivo selectivity of positive modulation of GABAA ɑ3 receptors in rats: a hard task
VL  - 26
IS  - Supplement 2
SP  - S290
EP  - S291
DO  - 10.1016/S0924-977X(16)31186-5
ER  - 

@conference{
author = "Batinić, Bojan and Stanković, Tamara and Poe, Michael M. and Cook, James M. and Savić, Miroslav",
year = "2016",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Neuropsychopharmacology",
title = "Attaining in vivo selectivity of positive modulation of GABAA ɑ3 receptors in rats: a hard task",
volume = "26",
number = "Supplement 2",
pages = "S290-S291",
doi = "10.1016/S0924-977X(16)31186-5"
}

Batinić, B., Stanković, T., Poe, M. M., Cook, J. M.,& Savić, M.. (2016). Attaining in vivo selectivity of positive modulation of GABAA ɑ3 receptors in rats: a hard task. in European Neuropsychopharmacology
Elsevier Science BV, Amsterdam., 26(Supplement 2), S290-S291.
https://doi.org/10.1016/S0924-977X(16)31186-5

Batinić B, Stanković T, Poe MM, Cook JM, Savić M. Attaining in vivo selectivity of positive modulation of GABAA ɑ3 receptors in rats: a hard task. in European Neuropsychopharmacology. 2016;26(Supplement 2):S290-S291.
doi:10.1016/S0924-977X(16)31186-5 .

Batinić, Bojan, Stanković, Tamara, Poe, Michael M., Cook, James M., Savić, Miroslav, "Attaining in vivo selectivity of positive modulation of GABAA ɑ3 receptors in rats: a hard task" in European Neuropsychopharmacology, 26, no. Supplement 2 (2016):S290-S291,
https://doi.org/10.1016/S0924-977X(16)31186-5 . .

TY  - CONF
AU  - Batinić, Bojan
AU  - Stanković, Tamara
AU  - Savić, Miroslav
PY  - 2016
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2685
PB  - Elsevier Science BV, Amsterdam
C3  - European Neuropsychopharmacology
T1  - Attaining in vivo selectivity of positive
modulation of a3 GABA-A receptors in
rats: a hard task
VL  - 26
IS  - Supplement 1
SP  - S42
EP  - S43
DO  - 10.1016/S0924-977X(16)70048-4
ER  - 

@conference{
author = "Batinić, Bojan and Stanković, Tamara and Savić, Miroslav",
year = "2016",
publisher = "Elsevier Science BV, Amsterdam",
journal = "European Neuropsychopharmacology",
title = "Attaining in vivo selectivity of positive
modulation of a3 GABA-A receptors in
rats: a hard task",
volume = "26",
number = "Supplement 1",
pages = "S42-S43",
doi = "10.1016/S0924-977X(16)70048-4"
}

Batinić, B., Stanković, T.,& Savić, M.. (2016). Attaining in vivo selectivity of positive
modulation of a3 GABA-A receptors in
rats: a hard task. in European Neuropsychopharmacology
Elsevier Science BV, Amsterdam., 26(Supplement 1), S42-S43.
https://doi.org/10.1016/S0924-977X(16)70048-4

Batinić B, Stanković T, Savić M. Attaining in vivo selectivity of positive
modulation of a3 GABA-A receptors in
rats: a hard task. in European Neuropsychopharmacology. 2016;26(Supplement 1):S42-S43.
doi:10.1016/S0924-977X(16)70048-4 .

Batinić, Bojan, Stanković, Tamara, Savić, Miroslav, "Attaining in vivo selectivity of positive
modulation of a3 GABA-A receptors in
rats: a hard task" in European Neuropsychopharmacology, 26, no. Supplement 1 (2016):S42-S43,
https://doi.org/10.1016/S0924-977X(16)70048-4 . .

TY  - JOUR
AU  - Timić-Stamenić, Tamara
AU  - Joksimović, Srđan
AU  - Biawat, Poonam
AU  - Stanković, Tamara
AU  - Marković, Bojan
AU  - Cook, James M.
AU  - Savić, Miroslav
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2314
AB  - Reportedly, negative modulation of alpha(5) GABA(A) receptors may improve cognition in normal and pharmacologically-impaired animals, and such modulation has been proposed as an avenue for treatment of cognitive symptoms in schizophrenia. This study assessed the actions of PWZ-029, administered at doses (2, 5, and 10 mg/kg) at which it reached micromolar concentrations in brain tissue with estimated free concentrations adequate for selective modulation of alpha(5) GABA(A) receptors, in three cognitive tasks in male Wistar rats acutely treated with the noncompetitive N-methyl-D-aspartate receptor antagonist, MK-801 (0.1 mg/kg), as well in tests of locomotor activity potentiated by MK-801 (0.2 mg/kg) or amphetamine (0.5 mg/kg). In a hormetic-like manner, only 5 mg/kg PWZ-029 reversed MK-801-induced deficits in novel object recognition test (visual recognition memory), whereas in the Morris water maze, the 2 mg/kg dose of PWZ-029 exerted partial beneficial effects on spatial learning impairment. PWZ-029 did not affect recognition memory deficits in social novelty discrimination procedure. Motor hyperactivity induced with MK-801 or amphetamine was not preventable by PWZ-029. Our results show that certain MK-801-induced memory deficits can be ameliorated by negative modulation of alpha(5) GABA(A) receptors, and point to the need for further elucidation of their translational relevance to cognitive deterioration in schizophrenia.
PB  - Sage Publications Ltd, London
T2  - Journal of Psychopharmacology
T1  - Negative modulation of alpha(5) GABA(A) receptors in rats may partially prevent memory impairment induced by MK-801, but not amphetamine- or MK-801-elicited hyperlocomotion
VL  - 29
IS  - 9
SP  - 1013
EP  - 1024
DO  - 10.1177/0269881115590601
ER  - 

@article{
author = "Timić-Stamenić, Tamara and Joksimović, Srđan and Biawat, Poonam and Stanković, Tamara and Marković, Bojan and Cook, James M. and Savić, Miroslav",
year = "2015",
abstract = "Reportedly, negative modulation of alpha(5) GABA(A) receptors may improve cognition in normal and pharmacologically-impaired animals, and such modulation has been proposed as an avenue for treatment of cognitive symptoms in schizophrenia. This study assessed the actions of PWZ-029, administered at doses (2, 5, and 10 mg/kg) at which it reached micromolar concentrations in brain tissue with estimated free concentrations adequate for selective modulation of alpha(5) GABA(A) receptors, in three cognitive tasks in male Wistar rats acutely treated with the noncompetitive N-methyl-D-aspartate receptor antagonist, MK-801 (0.1 mg/kg), as well in tests of locomotor activity potentiated by MK-801 (0.2 mg/kg) or amphetamine (0.5 mg/kg). In a hormetic-like manner, only 5 mg/kg PWZ-029 reversed MK-801-induced deficits in novel object recognition test (visual recognition memory), whereas in the Morris water maze, the 2 mg/kg dose of PWZ-029 exerted partial beneficial effects on spatial learning impairment. PWZ-029 did not affect recognition memory deficits in social novelty discrimination procedure. Motor hyperactivity induced with MK-801 or amphetamine was not preventable by PWZ-029. Our results show that certain MK-801-induced memory deficits can be ameliorated by negative modulation of alpha(5) GABA(A) receptors, and point to the need for further elucidation of their translational relevance to cognitive deterioration in schizophrenia.",
publisher = "Sage Publications Ltd, London",
journal = "Journal of Psychopharmacology",
title = "Negative modulation of alpha(5) GABA(A) receptors in rats may partially prevent memory impairment induced by MK-801, but not amphetamine- or MK-801-elicited hyperlocomotion",
volume = "29",
number = "9",
pages = "1013-1024",
doi = "10.1177/0269881115590601"
}

Timić-Stamenić, T., Joksimović, S., Biawat, P., Stanković, T., Marković, B., Cook, J. M.,& Savić, M.. (2015). Negative modulation of alpha(5) GABA(A) receptors in rats may partially prevent memory impairment induced by MK-801, but not amphetamine- or MK-801-elicited hyperlocomotion. in Journal of Psychopharmacology
Sage Publications Ltd, London., 29(9), 1013-1024.
https://doi.org/10.1177/0269881115590601

Timić-Stamenić T, Joksimović S, Biawat P, Stanković T, Marković B, Cook JM, Savić M. Negative modulation of alpha(5) GABA(A) receptors in rats may partially prevent memory impairment induced by MK-801, but not amphetamine- or MK-801-elicited hyperlocomotion. in Journal of Psychopharmacology. 2015;29(9):1013-1024.
doi:10.1177/0269881115590601 .

Timić-Stamenić, Tamara, Joksimović, Srđan, Biawat, Poonam, Stanković, Tamara, Marković, Bojan, Cook, James M., Savić, Miroslav, "Negative modulation of alpha(5) GABA(A) receptors in rats may partially prevent memory impairment induced by MK-801, but not amphetamine- or MK-801-elicited hyperlocomotion" in Journal of Psychopharmacology, 29, no. 9 (2015):1013-1024,
https://doi.org/10.1177/0269881115590601 . .